Navigation Links
In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
Date:6/23/2008

SCOTTSDALE, Ariz., June 23 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies hoping to identify the next blockbuster drug for pain management. The report, entitled "Thought Leader Insight & Analysis: Pain/Analgesics," is based on in-depth interviews conducted with a panel of specialists in anesthesiology, psychiatry, rheumatology, gastroenterology and primary care.

The diagnosis and treatment of nociceptive, neuropathic and somatic pain varies considerably depending on the physician specialty. MedPredict's panelists in each specialty outline their therapeutic goals and unmet needs in treating pain associated with cancer, fibromyalgia, trauma, rheumatoid and osteoarthritis, back injury, neuropathy, depression, migraine and Crohn's disease.

"Pain is subjective," said Dr. Jeffrey Berk, MedPredict's president. "If you think that you hurt, you hurt. This subjectivity makes the diagnosis and treatment of pain exceedingly difficult, and it presents enormous challenges for researchers trying to demonstrate analgesic efficacy versus placebo." One path to success will be to narrowly define the population being studied, as Lilly has done with duloxatine in diabetic neuropathy, according to Dr. Berk.

MedPredict's panelists predict successes and failures in a number of therapeutic targets, including mu receptor agonists/opioids, serotonergic/noradrenergics, sodium and calcium channel blockers, NMDA/glutamate, Alpha-2 agonist, (mGlu2/3), acetylcholine, AMPA, cannabinoid, NF Kappa b, TRPV1/vanilloids, stimulants, NSAIDs, hyaluronic acid, anti-IL-10 and anti-IL-1. They evaluate the development pipeline based on the medical potential, mechanism of action, reimbursement and regulatory environment and relevance of Schedule II status.

Companies/Partnerships discussed in this report include Allergan, Allergan/Acadia, Alpharma, Alpharma/Institut Biochimique, Amgen, Amgen
'/>"/>

SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Having Penetrated Israels Domestic Telephony Market, 012 Smile.Communications Prepares for Its Next Goal: Entering Israels Cellular Market
2. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
3. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
4. Biotech Avoids Fall Out From Tough Quarter for Capital Markets
5. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
6. pH Balanced RepHresh Vaginal Gel(R) now Available to Women in Canada Attacking Tough, Embarrassing Feminine Issues
7. Biotech Drops Amid Tough Markets in February
8. ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve
9. Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLCs Regulatory Announcement
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) has ... of bio-succinic acid used to produce a new ... that Bayer MaterialScience has begun commercializing.    ... eco, a series of bio-based waterborne polyurethane dispersions ... 65%.  IMPRANIL ® eco has been developed ...
(Date:4/24/2015)... April 24 , 2015 PAREXEL International ... services provider, today announced that Partnerships in Clinical Trials ... Management, the 2015 Clinical Innovator of the Year.  The ... team for the Company,s Perceptive MyTrials ® Data-Driven ... Thursday night during the 2015 Partnership Awards in ...
(Date:4/23/2015)... Dora, Florida (PRWEB) April 23, 2015 ... that it intends to conduct a groundbreaking pilot ... begin to be reversed in as little as ... the science of metabolic and nutritional medicine—will aggressively ... that cripple and destroy our aging brain. These ...
(Date:4/23/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... quarter 2015 results before the Nasdaq market opens on ... conference call and webcast to discuss its financial results ... 2015 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... call by dialing 866-952-1906 (US) or 785-424-1825 (International) using ...
Breaking Biology Technology:Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 2Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 3Bayer MaterialScience Names BioAmber As Its Supplier For New Product Line - Bio-succinic acid forms backbone of innovative new bio-based polyurethanes for textiles 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 2PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 3PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 4PAREXEL Honored With 2015 Clinical Innovator Of The Year Award From Partnerships In Clinical Trials 5New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... enhanced the abilities of the molecules they are creating ... molecular complexes enter cancer cells and, when signaled, deliver ... new supermolecules have more units that will absorb light ... frequencies that can be included and excluded as signals ...
... DNA isn't just for storing genetic codes any more. ... into larger structures -- scientists have been using it ... even working mechanical devices. , Now Cornell University researchers ... could be used for drug delivery and as containers ...
... have become invaluable decision-making tools for public health ... epidemic of 2001, models can be useful in ... of an infection and they can allow the ... models make implicit assumptions that may systematically bias ...
Cached Biology News:Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 2Virginia Tech group adds tools to DNA-targeted anti-cancer drugs 3Self-assembled DNA buckyballs for drug delivery 2Self-assembled DNA buckyballs for drug delivery 3Understanding biases in epidemic models important when making public health predictions 2
...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
Homo sapiens jumping translocation breakpoint...
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: